Susan M.  Kanaya net worth and biography

Susan Kanaya Biography and Net Worth

CFO of ChemoCentryx
Susan M. Kanaya serves as Chief Financial Officer, Executive Vice President, Chief Administrative Officer, Secretary of the Company. Since February 2006. From January 2006 to October 2016, Ms. Kanaya served as our Senior Vice President, Finance, and Chief Financial Officer. Prior to joining us, Ms. Kanaya served as Senior Vice President, Finance, and Chief Financial Officer at Kosan Biosciences Inc., a biotechnology company, from 1999 to 2005. Prior to this, she served in financial management positions at SUGEN, Inc., a biotechnology company, from 1994 to 1999, most recently as Vice President, Finance, and Treasurer. Ms. Kanaya also served as Controller with high technology companies and as a public accountant with KPMG. Ms. Kanaya received her B.S. in business administration from the University of California, Berkeley.

What is Susan M. Kanaya's net worth?

The estimated net worth of Susan M. Kanaya is at least $4.75 million as of August 16th, 2022. Ms. Kanaya owns 91,317 shares of ChemoCentryx stock worth more than $4,747,571 as of April 27th. This net worth approximation does not reflect any other investments that Ms. Kanaya may own. Additionally, Ms. Kanaya receives a salary of $845,040.00 as CFO at ChemoCentryx. Learn More about Susan M. Kanaya's net worth.

How old is Susan M. Kanaya?

Ms. Kanaya is currently 59 years old. There are 4 older executives and no younger executives at ChemoCentryx. The oldest executive at ChemoCentryx is Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman, who is 63 years old. Learn More on Susan M. Kanaya's age.

What is Susan M. Kanaya's salary?

As the CFO of ChemoCentryx, Inc., Ms. Kanaya earns $845,040.00 per year. There are 2 executives that earn more than Ms. Kanaya. The highest earning executive at ChemoCentryx is Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman, who commands a salary of $1,210,000.00 per year. Learn More on Susan M. Kanaya's salary.

How do I contact Susan M. Kanaya?

The corporate mailing address for Ms. Kanaya and other ChemoCentryx executives is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. ChemoCentryx can also be reached via phone at (650) 210-2900 and via email at [email protected]. Learn More on Susan M. Kanaya's contact information.

Has Susan M. Kanaya been buying or selling shares of ChemoCentryx?

Susan M. Kanaya has not been actively trading shares of ChemoCentryx during the last ninety days. Most recently, Susan M. Kanaya sold 19,898 shares of the business's stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $50.95, for a transaction totalling $1,013,803.10. Following the completion of the sale, the chief financial officer now directly owns 91,317 shares of the company's stock, valued at $4,652,601.15. Learn More on Susan M. Kanaya's trading history.

Who are ChemoCentryx's active insiders?

ChemoCentryx's insider roster includes Tausif Butt (COO), Markus Cappel (Treasurer), Thomas Edwards (Director), Susan Kanaya (CFO), Geoffrey Parker (Director), Thomas Schall (CEO), and James Tyree (Director). Learn More on ChemoCentryx's active insiders.

Susan M. Kanaya Insider Trading History at ChemoCentryx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2022Sell19,898$50.95$1,013,803.1091,317View SEC Filing Icon  
8/4/2022Sell46,298$50.17$2,322,770.6691,317View SEC Filing Icon  
6/12/2020Sell50,000$64.58$3,229,000.00121,317View SEC Filing Icon  
5/5/2020Sell20,123$54.73$1,101,331.79146,194View SEC Filing Icon  
2/19/2020Sell24,200$50.13$1,213,146.0091,317View SEC Filing Icon  
2/13/2020Sell45,300$49.61$2,247,333.0091,317View SEC Filing Icon  
2/11/2020Sell3,000$49.50$148,500.0091,317View SEC Filing Icon  
1/17/2020Sell15,737$41.03$645,689.1191,317View SEC Filing Icon  
11/26/2019Sell311,625$31.51$9,819,303.75162,931View SEC Filing Icon  
3/27/2019Sell35,000$13.05$456,750.00110,890View SEC Filing Icon  
1/22/2019Sell37,893$12.08$457,747.44110,746View SEC Filing Icon  
6/28/2018Sell49,507$13.79$682,701.5338,985View SEC Filing Icon  
6/26/2018Sell850$13.25$11,262.5038,985View SEC Filing Icon  
5/15/2018Sell8,306$11.14$92,528.8446,441View SEC Filing Icon  
5/8/2018Sell65,328$11.53$753,231.84103,463View SEC Filing Icon  
5/2/2018Sell1,366$11.50$15,709.0039,501View SEC Filing Icon  
1/22/2016Sell25,764$4.04$104,086.56View SEC Filing Icon  
1/20/2016Sell14,971$4.10$61,381.10View SEC Filing Icon  
1/19/2016Sell6,134$4.05$24,842.70View SEC Filing Icon  
1/15/2016Sell300$4.00$1,200.00View SEC Filing Icon  
1/8/2016Sell10,224$5.12$52,346.88View SEC Filing Icon  
1/6/2016Sell47,607$6.98$332,296.86View SEC Filing Icon  
1/5/2016Sell34,341$6.90$236,952.90View SEC Filing Icon  
1/4/2016Sell10,490$7.38$77,416.20View SEC Filing Icon  
6/28/2013Sell36,942$14.31$528,640.02View SEC Filing Icon  
5/30/2013Sell12,770$14.28$182,355.60View SEC Filing Icon  
10/1/2012Sell3,971$11.89$47,215.19View SEC Filing Icon  
See Full Table

Susan M. Kanaya Buying and Selling Activity at ChemoCentryx

This chart shows Susan M Kanaya's buying and selling at ChemoCentryx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ChemoCentryx Company Overview

ChemoCentryx logo
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $51.99
Low: $51.99
High: $51.99

50 Day Range

MA: $51.95
Low: $51.66
High: $51.99

2 Week Range

Now: $51.99
Low: $14.95
High: $52.00

Volume

113 shs

Average Volume

1,681,906 shs

Market Capitalization

$3.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22